Abstract: An abuse deterrent oral solid dosage form comprising: an inner portion comprising a drug susceptible to abuse and a pH dependent polymer soluble in acidic medium an outer portion, wherein the portion is devoid of drug susceptible to abuse and comprises an immediate release form of alkalizer and a sustained release form of alkalizer, the sustained release form of alkalizer comprising an alkalizer and a rate controlling excipient.

Abstract: An oral solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: An oral, solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: An oral solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: An oral, solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically pp acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: An abuse deterrent oral solid dosage form comprising: an inner portion comprising a drug susceptible to abuse and a pH dependent polymer soluble in acidic medium an outer portion, wherein the portion is devoid of drug susceptible to abuse and comprises an immediate release form of alkalizer and a sustained release form of alkalizer, the sustained release form of alkalizer comprising an alkalizer and a rate controlling excipient.

Abstract: An oral solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically acceptable excipients, wherein the mixture is an amorphous dispersion.

Abstract: A portable device for cutting a capsule which has been filled with a drug formulation is configured to allow for the accurate alignment of the capsule in the capsule holder and includes a blade shaped to cut the upper portion of the capsule so as to open and dispense the drug formulation without any spillage, and the cut end is disposed capably without falling back in the medication. The device operates accurately with different capsule sizes, even with smaller capsule size when dose content is low, and provides a reliable and precise technique for splitting capsules.

Abstract: A multi-particulate pharmaceutical composition suitable for administration in a sprinkle dosage form said particles being less than 2 mm in diameter and comprising a) inert core particles b) an inner layer surrounding said inert core particles, said layer comprising atorvastatin calcium, methyl methacrylate butyl methacrylate-dimethylaminoethyl methacrylate copolymer and disintegrant and c) an outer taste masking layer surrounding the inner layer, said outer layer comprising methyl methacrylate butyl methacrylate-dimethylaminoethyl methacrylate copolymer.

Abstract: A method of alleviating signs and symptoms of spasticity in human patient comprising orally administering to said human patients once in a day a controlled drug delivery system comprising an effective daily dose of baclofen or its pharmaceutically acceptable salt. The controlled drug delivery system is operable to produce a level of sedation lower than a sedation produced by three times a day immediate release tablets. A total daily dosage of the controlled release tablets and a total daily dosage of the three times a day immediate release tablets remain same.

Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from a swellable composition and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.

Abstract: The present invention provides a stable oral composition comprising a therapeutically effective amount of desloratadine and a stabilizer selected from the group comprising an antioxidant, a pharmaceutically acceptable organic compound that provides an alkaline pH, an alkali metal salt, or mixtures thereof, and pharmaceutically acceptable excipients.

Abstract: A stable oral pharmaceutical composition including a therapeutically effective amount of paroxetine or its pharmaceutically acceptable salt and one or more adjuvants that prevent the formation of pink hue upon storage of the composition. The composition can be prepared by aqueous granulation.

Abstract: The present invention provides a programmed drug delivery system comprising: (a) a core composition comprising one or more beneficial agents and pharmaceutically acceptable excipients, wherein at least one excipient swells when exposed to an aqueous environment, (b) a coat surrounding the core composition, wherein the coat is impermeable to the beneficial agent and other core components, but may be permeable or impermeable to water, (c) passageway in the coat, (d) a composition applied so as to cover the passageway, and optionally, an immediate release composition comprising the same or different beneficial agent.

Abstract: A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients and total impurities are present in amounts from 0% to not more than 3.3% w/w of the bupropion hydrochloride, when the composition is stored at 40° C. at 75% relative humidity for three months in closed containers with silica gel as dessicant.

Abstract: An oral pharmaceutical composition having reduced bitterness comprising therapeutically effective amounts of cetirizine or its pharmaceutically acceptable salts, alkaline earth oxide and a pharmaceutically acceptable carrier comprising a disintegrant wherein the composition disintegrates rapidly in the oral cavity.

Abstract: The present invention provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the pharmaceutical composition has enhanced oral bioavailability. The present invention also provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that the extent of absorption of metaxalone is independent of whether the composition is administered to the patient with food or on an empty stomach.

Abstract: A stable oral pharmaceutical formulation comprising ramipril or its pharmaceutically acceptable salt and a stabilizing amount of an ammoniomethacrylate copolymer in a pharmaceutically acceptable carrier medium is described.

Abstract: The present invention provides a stable pharmaceutical composition comprising gabapentin and pharmaceutically acceptable adjuvants, wherein the composition has an alkaline pH, and wherein at least one of the pharmaceutically acceptable adjuvants is a destabilizer.